[18 F ]FDG-PET/CT in adrenal lesions: diagnostic performance in different clinical settings.
Autor: | Romanisio M; Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy., Daffara T; Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy., Pitino R; Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy., Ferrero A; Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy., Pizzolitto F; Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy., Zavattaro M; Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy., Biello F; Oncology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy., Gennari A; Oncology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy., Volpe A; Division of Urology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy., Sacchetti GM; Unit of Nuclear Medicine, University Hospital 'Maggiore Della Carità', Corso Mazzini 18, 28100, Novara, Italy., Marzullo P; Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy., Aimaretti G; Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy., Prodam F; Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.; Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy., Caputo M; Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy. marina.caputo@uniupo.it.; Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy. marina.caputo@uniupo.it. |
---|---|
Jazyk: | angličtina |
Zdroj: | Endocrine [Endocrine] 2024 Sep 18. Date of Electronic Publication: 2024 Sep 18. |
DOI: | 10.1007/s12020-024-04042-5 |
Abstrakt: | Purpose: Data regarding [18 F ]FDG-PET/CT for the characterization of adrenal lesions are limited. Most of the studies proposed the tumor-to-liver maximum standardized uptake values (SUVratio) > 1.5 as the best cut off to predict malignancy. The aim of the study was to calculate the optimum cut off in a heterogeneous population with adrenal lesions and evaluate the diagnostic performance SUVratio >1.5. Patients and Methods: Retrospective analysis of adrenal lesions undergoing [18 F ]FDG-PET/CT (2013-2022) for different reasons (atypical adrenal incidentalomas, extra adrenal tumor staging). The diagnosis of benignity was assessed by: (i) histology; (ii) stability or minimal diameter increase (<20%/<5 mm) on 12-months follow-up for non-operated patients. The optimal SUVratio and performance of SUVratio >1.5 were calculated by ROC curves. Results: Forty-two consecutive lesions (diameter 36.1 ± 20.3 mm, 6 bilateral) underwent [18 F ]FDG-PET/CT (19F, age 61.2 ± 11.7 years). Twenty-nine lesions were benign, 11 malignant [8 metastases (2 bilateral) and 1 adrenocortical carcinoma (ACC)] and 2 pheochromocytomas. The SUVratio cut-off in our population was 1.55 (Sn 100%, Sp 73.7%, AUC 0.868), with similar values excluding pheochromocytomas and metastases (SUVratio cut-off 1.49, Sn 100%, Sp 96.3%, AUC 0.988). The SUVratio cut-off of 1.5 showed 100% Sn, 87% Sp, 73% PPV, and 100% NPV. Conclusion: [18 F ]FDG-PET/CT could help in decision making process avoiding unnecessary surgery. The SUVratio cut-off of 1.5 has a good performance in a heterogenous population. (© 2024. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: |